{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:14:24Z","timestamp":1791173664935,"version":"4.1.0"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>We have screened 47 locked nucleic acid (LNA) antisense oligonucleotides (ASOs) targeting conserved (&gt;95% homology) sequences in the hepatitis C virus (HCV) genome using the subgenomic HCV replicon assay and generated both antiviral (50% effective concentration [EC<jats:sub>50<\/jats:sub>]) and cytotoxic (50% cytotoxic concentration [CC<jats:sub>50<\/jats:sub>]) dose-response curves to allow measurement of the selectivity index (SI). This comprehensive approach has identified an LNA ASO with potent antiviral activity (EC<jats:sub>50<\/jats:sub>= 4 nM) and low cytotoxicity (CC<jats:sub>50<\/jats:sub>&gt;880 nM) targeting the 25- to 40-nucleotide region (nt) of the HCV internal ribosome entry site (IRES) containing the distal and proximal miR-122 binding sites. LNA ASOs targeting previously known accessible regions of the IRES, namely, loop III and the initiation codon in loop IV, had poor SI values. We optimized the LNA ASO sequence by performing a 1-nucleotide walk through the 25- to 40-nt region and show that the boundaries for antiviral efficacy are extremely precise. Furthermore, we have optimized the format for the LNA ASO using different gapmer and mixomer patterns and show that RNase H is required for antiviral activity. We demonstrate that RNase H-refractory ASOs targeting the 25- to 40-nt region have no antiviral effect, revealing important regulatory features of the 25- to 40-nt region and suggesting that RNase H-refractory LNA ASOs can act as potential surrogates for proviral functions of miR-122. We confirm the antisense mechanism of action using mismatched LNA ASOs. Finally, we have performed pharmacokinetic experiments to demonstrate that the LNA ASOs have a very long half-life (&gt;5 days) and attain hepatic maximum concentrations &gt;100 times the concentration required for<jats:italic>in vitro<\/jats:italic>antiviral activity.<\/jats:p>","DOI":"10.1128\/aac.00222-11","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T04:25:10Z","timestamp":1303187110000},"page":"3105-3114","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":52,"title":["Selection, Optimization, and Pharmacokinetic Properties of a Novel, Potent Antiviral Locked Nucleic Acid-Based Antisense Oligomer Targeting Hepatitis C Virus Internal Ribosome Entry Site"],"prefix":"10.1128","volume":"55","author":[{"given":"Carl","family":"Laxton","sequence":"first","affiliation":[{"name":"Internal Medicine, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Brady","sequence":"additional","affiliation":[{"name":"Pharmacokinetics, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sterghios","family":"Moschos","sequence":"additional","affiliation":[{"name":"Epigenetics, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Turnpenny","sequence":"additional","affiliation":[{"name":"Pharmacokinetics, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaiessh","family":"Rawal","sequence":"additional","affiliation":[{"name":"Pharmacokinetics, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Pryde","sequence":"additional","affiliation":[{"name":"Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sidders","sequence":"additional","affiliation":[{"name":"BioInformatics, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romu","family":"Corbau","sequence":"additional","affiliation":[{"name":"Internal Medicine, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Pickford","sequence":"additional","affiliation":[{"name":"Epigenetics, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Murray","sequence":"additional","affiliation":[{"name":"Internal Medicine, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.1999.00552.x"},{"key":"e_1_3_3_3_2","first-page":"707","article-title":"Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides","volume":"22","author":"Alt M.","year":"1995","unstructured":"AltM. RenzR. HofschneiderP. H. PaumgartnerG. CaselmannW. H.. 1995. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 22:707\u2013717.","journal-title":"Hepatology"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.010909.105654"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.5.3181-3190.2003"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkf651"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/157488710792007293"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/125435"},{"key":"e_1_3_3_9_2","unstructured":"CrookeS. T.(ed.). 2007. Antisense drug technology: principles strategies and applications p. 537\u2013558. CRC Press Boca Raton FL."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01304-06"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161208786898770"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkp553"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06783"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.18997-0"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0270-9139(03)80355-5"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200721040-00004"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.8.5203-5212.1996"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2008.244"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00417-10"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1113329"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409834102"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.09.023"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr050266u"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04303"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/30.9.1911"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1178178"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1042\/BST0381553"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.1.626"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.09.009"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01156-09"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0235524100"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1261\/rna.1680809"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1902"},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/135965350400900612","article-title":"Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment","volume":"9","author":"Soler M.","year":"2004","unstructured":"SolerM. McHutchisonJ. G. KwohT. J. DorrF. A. PawlotskyJ. M.. 2004. Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment. Antivir. Ther. 9:953\u2013968.","journal-title":"Antivir. Ther."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006661"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl1071"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.3.1476-1483.1992"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.4161\/rna.6.3.8807"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.07.004"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2003.12.012"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.10.5633"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)36775-3"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030108"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00222-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00222-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T10:58:26Z","timestamp":1686049106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00222-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1128\/AAC.00222-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00222-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"2011-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-06-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}